Skip to content

    Recently Viewed

      Listening...

      A female doctor in a lab coat pointing to an xray of lungs on a tablet while explaining something to two seated patients.

      By the numbers: Who gets lung cancer?

      Each year, more people die of lung cancer than colon, breast and prostate cancers combined. Learn how Johnson & Johnson is dedicated to improving outcomes by integrating the company’s MedTech and Innovative Medicine expertise.

      Share Article
      share to

      Lung cancer is—by far—the leading cause of all cancer deaths across the globe, with 1.8 million people dying from the disease each year. Part of the reason has to do with the fact that early symptoms mimic common respiratory illnesses, so people with lung cancer often aren’t diagnosed until their cancer has reached an advanced stage.

      Also at play? The “typical” patient is no longer so typical. Smokers, in other words, aren’t the only people at risk. Anyone who has a family history of the disease or is exposed to secondhand smoke and air pollution is also vulnerable.

      But advances in early detection and breakthrough treatments are helping improve lung cancer outcomes. For one, the American Cancer Society recently updated its screening guidelines, recommending that people between the ages of 50 and 80 who smoke or formerly smoked 20 or more packs a year get screened annually.

      And when it comes to developing innovative treatments, Interventional Oncology at Johnson & Johnson is focused on integrating the company’s MedTech and Innovative Medicine expertise to deliver therapies directly into lung tumors via minimally invasive procedures.

      For Lung Cancer Awareness Month, here’s a look at the prevalence, diagnosis and mortality rates of lung cancer worldwide—and how Johnson & Johnson is playing a role in improving the lives of patients.

      Infographic of who gets lung cancer on a red and white background

      More ways Johnson & Johnson is working to fight lung cancer

      See how researchers are developing preventive approaches for early detection, creating new therapies and more.

      More from Johnson & Johnson

      Innovation
      Close-up of a woman with low vision receiving an eye exam exam with a doctor shining light into her left eye

      What is low vision?

      Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
      Innovation
      A female scientist conducting research in a laboratory, focusing on orphan drugs for rare diseases

      What is an orphan drug?

      The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
      Caring & giving
      Sam Seavey piloting an aircraft from the cockpit

      3 health advocates; 1 Johnson & Johnson program that offers empowerment and connection

      In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.